Captor Therapeutics (CTX.WA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CTX.WA · Stock Price

PLN 77.30+42.30 (+120.86%)

Market Cap: $121.2M

Historical price data

Market Cap: $121.2MPipeline: 1 drugFounded: 2017Employees: 50-100HQ: Wroclaw, Poland

Sector Ranking#218 in Small Molecule Drugs #74 in Oncology (General)

Overview

Captor Therapeutics is a clinical-stage biotech focused on unlocking the 'undruggable' proteome through targeted protein degradation. Founded in 2017 and publicly listed in Warsaw, the company has validated its scientific approach by securing substantial EU and Polish grant funding and advancing its lead MCL-1 degrader, CT-03, toward clinical trials. Its strategy combines world-class R&D in Wroclaw with strategic business development in Basel to build a leading European TPD franchise.

OncologyAutoimmune Diseases

Technology Platform

Optigrade™ - An integrated drug discovery platform combining computational biology, structural chemistry, and proteomics to rationally design and optimize bifunctional degraders (PROTACs) and molecular glues for targeted protein degradation.